What is Endonovo Therapeutics, Inc. (ENDV)?

Endonovo Therapeutics, Inc. (ENDV) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ENDV?

The current price of ENDV is $0.00. Prices are updated in real time on Stocks360.

What is ENDV's price-to-earnings (PE) ratio?

ENDV's trailing twelve-month PE ratio is -0.10, based on current price and earnings per share data available on Stocks360.

What is ENDV's market capitalization?

ENDV's market capitalization is $15,938.00, placing it in the small-cap tier.

Endonovo Therapeutics, Inc. (ENDV)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$15.94K

PE (TTM)

-0.10

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-8.36

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.00

Avg Volume

N/A

Volume

500.00K

Endonovo Therapeutics, Inc. (ENDV) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $15.94K. Trailing PE -0.10. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $0.00 2026-10-28 · $0.00 (-75.00%)

Proprietary Signals

Signal snapshot temporarily unavailable.

About Endonovo Therapeutics, Inc.

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.10×
P/S (TTM)	0.00×
P/B	-0.00×
P/FCF (TTM)	-0.14×
EV / EBITDA	-6.87×
EV / Sales	0.00×
Earnings Yield	-2500.72%
Free Cash Flow Yield	-736.73%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$7.03M
Net Income (TTM)	-$398.56K
Free Cash Flow (TTM)	$1.12M
Net Debt	$7.01M
Working Capital	-$29.97M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	7.75%
Return on Invested Capital	4.46%